Immune-Related Pancreatitis Caused by Immune Checkpoint Inhibitor Nivolumab:Report of One Case.
10.3881/j.issn.1000-503X.15003
- Author:
Feng XU
1
;
Zhu SHEN
1
;
Hong TAO
1
;
Zhu ZHU
1
;
Jia-Long TAO
2
;
Zheng-Yang FENG
2
Author Information
1. Department of Pharmacy,the Second Affiliated Hospital of Soochow University,Suzhou,Jiangsu 215004,China.
2. Department of Oncology,the Second Affiliated Hospital of Soochow University,Suzhou,Jiangsu 215004,China.
- Publication Type:Journal Article
- Keywords:
adverse reaction associated with immunotherapy;
immune checkpoint inhibitor;
immune-related pancreatitis
- MeSH:
Humans;
Nivolumab/adverse effects*;
Immune Checkpoint Inhibitors/adverse effects*;
Antineoplastic Agents, Immunological/adverse effects*;
Pancreatitis/drug therapy*;
Stomach Neoplasms
- From:
Acta Academiae Medicinae Sinicae
2023;45(2):351-354
- CountryChina
- Language:Chinese
-
Abstract:
In recent years,great progress has been achieved in the application of immune checkpoint inhibitors (ICI) in tumor immunotherapy.However,a variety of adverse reactions induced by ICI have been reported.Despite the high overall incidence of adverse reactions caused by ICI,some adverse reactions,such as immune-related pancreatitis,are rare in clinical practice.In this paper,a case of immune-related pancreatitis after treatment of advanced gastric cancer with nivolumab was identified.We analyzed the cause,treatment,incidence,and risk factors of the adverse reaction,aiming to improve the clinical diagnosis,treatment,and safe medication of rare adverse reactions associated with ICI.
